Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on January 17, 2019, covering events reported as of that date. The filing primarily addresses a Regulation FD disclosure regarding a strategic investment transaction.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company. The report focuses exclusively on equity ownership percentages resulting from a recent transaction.
Material Changes
On January 23, 2019, the Company purchased an additional equity stake in Rafael Pharmaceuticals, Inc. Following this transaction:
- The Company owns securities representing 51.0% of the outstanding capital stock of Rafael Pharmaceuticals.
- Of the 51.0% stake, 12.3% is beneficially held by co-investors in subsidiaries of the Company.
- On a fully diluted basis (excluding a remaining warrant held by a subsidiary), the Company owns 39.5% of the capital stock.
- Of the 39.5% fully diluted stake, 9.5% is beneficially held by co-investors in subsidiaries of the Company.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure that the information is furnished pursuant to Item 7.01 and is not deemed "filed" with the SEC for incorporation by reference into other filings.
Investor Verification Checklist
- Verify the exact terms of the purchase agreement for the additional equity stake in Rafael Pharmaceuticals, Inc.
- Confirm the valuation of Rafael Pharmaceuticals, Inc. implied by the transaction.
- Review the attached Press Release (Exhibit 99.1) for details on the co-investor structure and the remaining warrant.
- Check subsequent filings for the impact of this investment on the Company's consolidated financial statements.